Inquiry

Angioimmunoblastic T-cell lymphoma (AITL)

Angioimmunoblastic T-cell lymphoma (AITL), also referred to as angioimmunoblastic lymphadenopathy with dysproteinemia, is characterized by a varied infiltration of lymph nodes displaying a notable rise in high endothelial venules (HEVs) and follicular dendritic cells (FDCs). Our company remains at the forefront of scientific advancements in rare diseases, enabling us to deliver innovative and efficacious solutions for the development of drugs and therapies targeting AITL.

Overview of Angioimmunoblastic T-cell Lymphoma (AITL)

• Definition of AITL
  Angioimmunoblastic T-cell lymphoma (AITL) is a type of mature T-cell lymphoma characterized by the presence of immunoblasts in blood or lymph vessels. The average incidence of AITL is less than 1/100 000. It accounts for approximately 15-20% of peripheral T-cell lymphomas and 1-2% of all non-Hodgkin lymphomas. AITL commonly involves multiple organs throughout the body. It primarily affects older adults and is characterized by the proliferation of abnormal T-cells in the lymph nodes and other organs.
• Pathogenesis of AITL
  The pathogenesis of AITL involves complex molecular and genetic alterations. Recent studies have identified several key mutations associated with AITL development. For instance, mutations in the IDH2R172 gene have been observed in a subset of AITL cases, suggesting its potential role in disease pathogenesis.
  Furthermore, T-cell receptor (TCR)-related gene variations, such as those affecting TET2, DNMT3A, and RHOA, have been implicated in AITL. These mutations contribute to dysregulated epigenetic regulation, altered gene expression, and impaired T-cell differentiation, ultimately resulting in the development of AITL.

Therapeutics Development of AITL

• Targets of AITL Therapy Development
  • Understanding the specific molecular targets in AITL is crucial for developing effective therapies. One notable target in AITL is the non-canonical NFκB pathway, which is frequently activated in AITL cases. This pathway plays a significant role in the survival and proliferation of malignant T-cells in AITL.
  • Other potential therapeutic targets include RC3H1/Roquin and GAPDH, which have been implicated in AITL pathogenesis. By targeting these specific molecules and pathways, novel therapies can be developed to combat AITL.
• Types of AITL Therapy Development
  • Immunotherapies: An effective strategy involves the utilization of immunotherapies, including immune checkpoint inhibitors, which can augment the immune system's capacity to identify and eradicate cancerous cells.

  • Targeted Therapies: The development of small molecule inhibitors targeting specific mutations, such as IDH2 inhibitors, holds promise for personalized therapy strategies in AITL.

Our Services

With an experienced team including researchers and scientists, our company provides a one-stop diagnostics and therapy development service to accelerate your AITL research. Our company is equipped with state-of-the-art facilities that enable us to conduct cutting-edge research and provide high-quality services. We understand that every research project is unique, and that's why we offer customized services tailored to your specific requirements.

Therapy Development Platforms

We specialize in the generation of genetically engineered models (GEMs) that accurately mimic the molecular and genetic features of AITL. These models serve as powerful tools for pharmacokinetics study and drug safety evaluation. Utilizing our specialized knowledge, we are capable of offering dependable and pertinent animal models that can expedite your research on angioimmunoblastic T-cell lymphoma (AITL).

Animal Models of AITL

If you are interested in our services, please feel free to contact us for more details and quotation information of related services.

References

• Chiba, Shigeru, and Mamiko Sakata-Yanagimoto. "Advances in the understanding of angioimmunoblastic T-cell lymphoma." Leukemia 34.10 (2020): 2592-2606.
• Mohammed Saleh, Mostafa F., et al. "Recent advances in diagnosis and therapy of angioimmunoblastic T cell lymphoma." Current Oncology 28.6 (2021): 5480-5498.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Large Granular Lymphocytic Leukemia (LGLL)
• Primary Cutaneous T-cell lymphoma (CTCL)
• Peripheral T-cell Lymphoma (PTCL)